U.S. Markets closed

OncoSec Medical Incorporated (ONCS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.20+0.01 (+0.19%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.19
Open5.22
Bid5.19 x 900
Ask5.21 x 800
Day's Range4.90 - 5.25
52 Week Range1.04 - 5.77
Volume205,967
Avg. Volume270,542
Market Cap143.98M
Beta (5Y Monthly)2.55
PE Ratio (TTM)N/A
EPS (TTM)-2.56
Earnings DateDec 06, 2017 - Dec 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.13
  • OncoSec Announces Exclusive License Agreement for Cliniporator® Gene Electrotransfer Platform Developed by IGEA Clinical Biophysics
    PR Newswire

    OncoSec Announces Exclusive License Agreement for Cliniporator® Gene Electrotransfer Platform Developed by IGEA Clinical Biophysics

    OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company developing intra-tumoral cancer immunotherapies, today announced that it has licensed the exclusive rights to the Cliniporator® electroporation or gene electrotransfer platform from IGEA Clinical Biophysics ("IGEA"). The license encompasses a broad field of use for gene delivery in oncology, including use as part of OncoSec's visceral lesion applicator (VLA) program. Additionally, the U.S. Food and Drug Administration (FDA) has cleared the Cliniporator platform for use in the upcoming Phase 1 trial to be held at Providence Health investigating CORVax12, the Company's DNA-encodable vaccine candidate for COVID-19. CORVax12 combines TAVO™ (tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (IL-12), with the National Institute of Health (NIH)'s SARS-CoV-2 virus "spike" protein.

  • OncoSec Provides Highlights from Analyst & Investor Day and SITC 2020 and Announces KEYNOTE-695 Reaches Full Enrollment
    PR Newswire

    OncoSec Provides Highlights from Analyst & Investor Day and SITC 2020 and Announces KEYNOTE-695 Reaches Full Enrollment

    OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today provided highlights from its Analyst & Investor Day and Symposium held at the Society for Immunotherapy of Cancer (SITC)'s 35th Anniversary Annual Meeting. KOLs shared their views and insights regarding the Company's positive interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial evaluating TAVO™ (tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (IL-12), in combination with KEYTRUDA® (pembrolizumab) in rigorously defined anti-PD1 checkpoint resistant metastatic melanoma patients as well as other programs leveraging TAVO and its gene electrotransfer platform. The Company also announced that KEYNOTE-695 is now fully enrolled.

  • OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020
    PR Newswire

    OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020

    OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced new positive interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial evaluating TAVO™ (tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (IL-12), in combination with KEYTRUDA® (pembrolizumab) in rigorously defined anti-PD1 checkpoint resistant metastatic melanoma patients.